The invention relates to the use of a phosphodiesterase type III (PDE III)inhibitor or Ca2+ -sensitizing agent or a pharmaceutically acceptablederivative thereof for the preparation of a medication for the reduction ofthe heart size of a patient suffering from heart failure.